Related Experiment Video
Updated: Jun 3, 2026
07:31
Nitropeptide Profiling and Identification Illustrated by Angiotensin II
Published on: June 16, 2019
Angiotensin peptides and lung cancer
Patricia E Gallagher1, Katherine Cook, David Soto-Pantoja
1Hypertension and Vascular Research Center, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA. pgallagh@wfubmc.edu
Current Cancer Drug Targets
|March 15, 2011
Summary
Lung cancer has a poor prognosis, necessitating new treatments. This review explores the renin-angiotensin system
Area of Science:
- Oncology
- Cardiovascular Research
- Molecular Biology
Background:
- Lung cancer remains a significant global health challenge with low survival rates.
- The renin-angiotensin system regulates blood pressure and has emerging roles in cell proliferation and inflammation.
Purpose of the Study:
- To review the role of the renin-angiotensin system in lung cancer.
- To evaluate the potential of targeting this system for lung cancer treatment and prevention.
Main Methods:
- Literature review of studies on the renin-angiotensin system and pulmonary cancers.
- Analysis of the effects of angiotensin II and angiotensin-(1-7) on cancer cells.
Main Results:
- Angiotensin II exhibits mitogenic and angiogenic properties relevant to cancer growth.
- Angiotensin-(1-7) demonstrates anti-proliferative and anti-angiogenic effects.
Conclusions:
- The renin-angiotensin system is implicated in lung cancer development.
- Modulating this pathway may offer novel therapeutic and preventive strategies for lung cancer.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...